Research & Development
Widespread HbA1c screening enables earlier type 2 diabetes diagnosis in U.K. study
HbA1c screening in adults between 40 and 70 years of age can reduce the time to diabetes diagnosis by a median of 2.2 years compared with routine clinical care, the authors found.
November 22, 2022
LumiraDx announces commercial expansion of HbA1c test
The LumiraDx HbA1c test is an actively controlled microfluidic assay that provides results in seven minutes in a near-patient setting.
November 14, 2022
COVID-19 escalates risk for type 1 diabetes: Norway study
The study, conducted by the Norwegian Institute of Public Health (NIPH) in Oslo, Norway, used national health registers to examine new-onset type 1 diabetes diagnoses in all youngsters under 18 in Norway (more than 1.2 million individuals) over the course of two years.
September 26, 2022
Glucose testing market to reach $27.1B by 2027: Kalorama
With a compound annual growth rate (CAGR) anticipated at 5.9%, the market is expected to reach $27.1 billion by 2027, said the report published by LabPulse.com's sister brand Kalorama Information.
September 18, 2022
Biosensor developer Know Labs goes public on the NYSE
After the close of trading Thursday, the company announced the pricing of an underwritten public offering of 3.6 million shares at $2.00 per share; it granted to the underwriter a 45-day option to purchase up to 540,000 additional shares at the same price.
September 15, 2022
USPSTF: more evidence needed on diabetes screening
The Task Force concluded that more research is needed to recommend for or against screening children and adolescents without signs or symptoms.
September 12, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
‘Good’ cholesterol worse for some adults: NIH study
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Long COVID outpaces diabetes in 2022 employer health spending
The firm said that it conducted an extensive study to examine the costs of long COVID and its associated conditions -- breathing abnormalities, malaise and fatigue, cough, throat and chest pain, and respiratory failure.
August 30, 2022
Precision Diabetes, DxGen to launch diabetes analyzer
The analyzer will include hemoglobin A1c, C-reactive protein, and urinary albumin tests, and add other tests later.
August 21, 2022
Renalytix underscores KidneyIntelX clinical results
Specifically, the results show that these physicians understand the value of the test in determining treatment decisions for adults with type 2 diabetes and early chronic kidney disease stages 1 to 3, also known as diabetic kidney disease, the firm said.
August 7, 2022
Roche H1 diagnostics revenues up 10% year over year
The firm posted core laboratory revenues of CHF 3.88 billion, up 3% year-over-year from CHF 3.77 billion; point-of-care revenues of CHF 2.61 billion, up 45% year-over-year from CHF 1.80 billion; molecular laboratory revenues of CHF 1.98 billion, down 1% year-over-year from CHF 1.99 billion; diabetes care revenues for CHF 832 million, down 7% year-over-year from CHF 894 million; and pathology laboratory revenues of CHF 652 million, up 11% year-over-year from CHF 590 million.
July 20, 2022
GBS study compares glucose levels in saliva, blood
The developer of a biosensor platform for point-of-care testing said it will now perform statistical analyses of the correlation of glucose levels among the sample types.
July 13, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Page 1 of 5